161 related articles for article (PubMed ID: 37565582)
1. MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
Nakanishi T; Yoneshima Y; Okamura K; Yanagihara T; Hashisako M; Iwasaki T; Haratake N; Mizusaki S; Ota K; Iwama E; Takenaka T; Tanaka K; Yoshizumi T; Oda Y; Okamoto I
Cancer Sci; 2023 Oct; 114(10):4101-4113. PubMed ID: 37565582
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
Huang J; Weng Q; Shi Y; Mao W; Zhao Z; Wu R; Ren J; Fang S; Lu C; Du Y; Ji J
FEBS Open Bio; 2020 Jun; 10(6):1065-1071. PubMed ID: 32237066
[TBL] [Abstract][Full Text] [Related]
3. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
Jiang K; Zou H
Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
[TBL] [Abstract][Full Text] [Related]
4. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
[TBL] [Abstract][Full Text] [Related]
5. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
Wei S; Wang K; Huang X; Zhao Z; Zhao Z
Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
[TBL] [Abstract][Full Text] [Related]
6. The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.
Lin J; Qiu Y; Zheng X; Dai Y; Xu T
BMC Cancer; 2022 Jul; 22(1):756. PubMed ID: 35818041
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression.
Nishizawa N; Shimajiri S; Oyama R; Manabe T; Nemoto Y; Matsumiya H; Honda Y; Taira A; Takenaka M; Kuroda K; Tanaka F
Sci Rep; 2023 Dec; 13(1):21687. PubMed ID: 38065981
[TBL] [Abstract][Full Text] [Related]
8. Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a.
Chen Y; Song W; Gao Y; Dong X; Ji X
Tohoku J Exp Med; 2022 May; 257(1):33-43. PubMed ID: 35354691
[TBL] [Abstract][Full Text] [Related]
9. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
11. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
[TBL] [Abstract][Full Text] [Related]
12. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
Shadbad MA; Asadzadeh Z; Derakhshani A; Hosseinkhani N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Brunetti O; Argentiero A; Racanelli V; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Nov; 143():112213. PubMed ID: 34560556
[TBL] [Abstract][Full Text] [Related]
13. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
14. [Effect of
Yuan J; Han H; Dong W; Wang RC; Hao HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):96-103. PubMed ID: 36765483
[TBL] [Abstract][Full Text] [Related]
15. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
Zhang N; Fan J; Deng Z
Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Liu W; Liu R; Yuan R; Wang X
Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
[TBL] [Abstract][Full Text] [Related]
17. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway.
Niu R; Li D; Chen J; Zhao W
Cell Cycle; 2022 Jan; 21(1):86-100. PubMed ID: 34919024
[TBL] [Abstract][Full Text] [Related]
18. Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer.
Hisakane K; Seike M; Sugano T; Matsuda K; Kashiwada T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Gemma A
Gene; 2023 Mar; 857():147177. PubMed ID: 36623674
[TBL] [Abstract][Full Text] [Related]
19. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
20. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
